Concepedia

Brian D. Harms

BD

Statistics

Publications

14

Citations

1.6K

H-Index

14

Active since

1998

Affiliations

Merrimack Pharmaceuticals (United States)(Current)

Technical University of Munich

Centre National de la Recherche Scientifique

University of Freiburg

German Cancer Research Center

Brian D. Harms is an author at Merrimack Pharmaceuticals (United States) specializing in life sciences, molecular oncology, and molecular biology.

Publications per year

1998–2019

14

Publications

14

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

Birgit Schoeberl, Emily A. Pace, Jonathan B. Fitzgerald et al. · Science Signaling · 2009 · 368 citations

Life Sciences, Cell Biology, Molecular Biology +17

Lessons Learned from Quantitative Dynamical Modeling in Systems Biology

Andreas Raue, Marcel Schilling, Julie Bachmann et al. · PLoS ONE · 2013 · 361 citations · Full text

Life Sciences, Systems Biology, Biological Systems Modeling +13

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms et al. · Molecular Cancer Therapeutics · 2012 · 275 citations · Full text

Medicine, Oncology, Pharmacology +17

Directional Persistence of EGF-Induced Cell Migration Is Associated with Stabilization of Lamellipodial Protrusions

Brian D. Harms, Gina M. Bassi, Alan Rick Horwitz et al. · Biophysical Journal · 2005 · 126 citations · Full text

Life Sciences, Cell Biology, Cell Adhesion +15

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum et al. · Molecular Cancer Therapeutics · 2013 · 102 citations

Life Sciences, Oncology, Pharmacology +17

1–5 of 14